US · EXEL · BIOTECHNOLOGY
Exelixis, Inc. (EXEL) intrinsic value and stock valuation
$64.63as of 2026-11-21 · Mkt cap 14.25B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Exelixis, Inc. DCF and intrinsic value
InvestorsCraft values EXEL with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from EXEL’s statements →
Exelixis, Inc. Graham Number
Graham Number: $22.72d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2026, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Revolution Medicines, Inc. (RVMD) $161.20
- Moderna, Inc. (MRNA) $195.00
- BridgeBio Pharma, Inc. (BBIO) $76.03
- Align Technology, Inc. (ALGN) $155.17
- Madrigal Pharmaceuticals, Inc. (MDGL) $379.10
- BioMarin Pharmaceutical Inc. (BMRN) $60.41
- Bio-Techne Corporation (TECH) $72.67
- Halozyme Therapeutics, Inc. (HALO) $91.35
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2026 | 2025 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| Operating income | $872.2M | $604.6M | $170.9M | $201.5M | $286.7M |
| Net income | $782.6M | $521.3M | $207.8M | $182.3M | $231.1M |
| EPSd | $2.78M | $1.76M | $646.3K | $561.6K | $716.8K |
| Operating cash flow | $884.3M | $700M | $333.3M | $362.6M | $400.8M |
| Capital expenditure | -$-39.93M | -$-66.19M | -$-162.97M | -$-138.46M | -$-64.22M |
| Free cash flow | $844.3M | $633.8M | $170.4M | $224.2M | $336.6M |
| Total assets | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B |
| Total debt | $173M | $190.8M | $189.9M | $190.2M | $51.3M |
| Net debt | -$-309.45M | -$-26.55M | -$-73.05M | -$-311.02M | -$-595.9M |
| Total equity | $2.16B | $2.24B | $2.26B | $2.49B | $2.21B |
| Cash and short-term investments | $1.06B | $1.11B | $995.3M | $1.31B | $1.47B |
Income statement
| 2026 | 2025 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| Cost of revenue | $83.7M | $76.2M | $72.6M | $57.9M | $52.9M |
| Gross profit | $2.24B | $2.09B | $1.76B | $1.55B | $1.38B |
| Research and development expenses | $825M | $910.4M | $1.04B | $891.8M | $693.7M |
| Selling, general and administrative expenses | $518.7M | $492.1M | $542.7M | $459.9M | $401.7M |
| Other expenses | $20.5M | $85.3M | $0.00 | -$-200K | -$-180K |
| Operating expenses | $1.36B | $1.49B | $1.59B | $1.35B | $1.1B |
| Cost and expenses | $1.45B | $1.56B | $1.66B | $1.41B | $1.15B |
| Interest income | $69.2M | $77.2M | $86.5M | $33.1M | $7.67M |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $29.1M | $28.8M | $25.7M | $20.9M | $13.6M |
| Ebitda | $921.8M | $718.8M | $283.2M | $255.2M | $307.8M |
| Operating income | $872.2M | $604.6M | $170.9M | $201.5M | $286.7M |
| Total other income/expenses, net | $69M | $77M | $86.6M | $32.9M | $7.49M |
| Income before tax | $941.2M | $681.6M | $257.5M | $234.4M | $294.2M |
| Income tax expense | $158.6M | $160.4M | $49.8M | $52.1M | $63.1M |
| Net income | $782.6M | $521.3M | $207.8M | $182.3M | $231.1M |
| Weighted average shares outstanding | $271.6M | $290M | $318.2M | $321.5M | $314.9M |
| Weighted average diluted shares outstanding | $281.9M | $296.1M | $321.5M | $324.6M | $322.4M |
Balance sheet
| 2026 | 2025 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.06B | $1.11B | $995.3M | $1.31B | $1.47B |
| Net receivables | $286.9M | $265.4M | $237.4M | $214.8M | $285.6M |
| Inventory | $21.7M | $22.4M | $17.3M | $33.3M | $27.5M |
| Total current assets | $1.44B | $1.47B | $1.32B | $1.62B | $1.83B |
| Property, plant and equipment, net | $441.3M | $359.1M | $470.9M | $345.4M | $104M |
| Goodwill and intangible assets | $63.7M | $63.7M | $63.7M | $63.7M | $63.7M |
| Long-term investments | $603.6M | $637.3M | $728.7M | $756.7M | $371.1M |
| Total non-current assets | $1.4B | $1.48B | $1.62B | $1.45B | $781.5M |
| Total assets | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B |
| Accounts payable | $29.6M | $38.2M | $33.8M | $32.7M | $24.3M |
| Short-term debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $7.49M | $7.81M |
| Total current liabilities | $405.6M | $403.8M | $394.3M | $324.4M | $337.6M |
| Long-term debt | $173M | $190.8M | $189.9M | $190.2M | $51.3M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $6.58M | $8.74M |
| Total non-current liabilities | $277.5M | $299.7M | $284.2M | $258.7M | $68M |
| Capital lease obligations | $173M | $190.8M | $189.9M | $190.2M | $51.3M |
| Total liabilities | $683.1M | $703.5M | $678.5M | $583.1M | $405.6M |
| Common stock | $260K | $280K | $300K | $320K | $320K |
| Retained earnings | -$-76.83M | -$-98.65M | -$-173.35M | -$-34.23M | -$-216.51M |
| Accumulated other comprehensive income (loss) | $3.48M | -$-1.35M | -$-3.75M | -$-14.52M | -$-760K |
| Total equity | $2.16B | $2.24B | $2.26B | $2.49B | $2.21B |
| Total investments | $1.18B | $1.53B | $1.46B | $1.56B | $1.19B |
| Total debt | $173M | $190.8M | $189.9M | $190.2M | $51.3M |
| Net debt | -$-309.45M | -$-26.55M | -$-73.05M | -$-311.02M | -$-595.9M |
Cash flow statement
| 2026 | 2025 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $782.6M | $521.3M | $207.8M | $182.3M | $231.1M |
| Depreciation and amortization | $29.1M | $28.8M | $25.7M | $20.9M | $13.6M |
| Stock-based compensation | $113M | $93.8M | $106.3M | $107.6M | $119.8M |
| Change in working capital | -$-191.2M | -$-13.45M | -$-13.97M | -$-12.8M | -$-39.01M |
| Accounts receivable | -$-21.4M | -$-27.95M | -$-22.62M | $66.9M | -$-122.32M |
| Inventory | $12.2M | $5.45M | -$-12.98M | -$-11.68M | -$-13.21M |
| Accounts payable | -$-50.15M | -$-21.89M | $53.3M | $23.4M | $55.1M |
| Net cash provided by operating activities | $884.3M | $700M | $333.3M | $362.6M | $400.8M |
| Investments in property, plant and equipment | -$-8.43M | -$-28.43M | -$-40.47M | -$-27.71M | -$-54.23M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $350.4M | -$-116.78M | -$-26.95M | -$-524.41M | -$-42.88M |
| Common stock issued | $49.1M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-947.51M | -$-652.03M | -$-550.38M | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-969.59M | -$-628.81M | -$-546.05M | $590K | -$-14.8M |
| Net change in cash | $265.1M | -$-45.62M | -$-239.68M | -$-161.21M | $343.1M |
| Cash at end of period | $482.5M | $217.4M | $263M | $502.7M | $663.9M |
| Operating cash flow | $884.3M | $700M | $333.3M | $362.6M | $400.8M |
| Capital expenditure | -$-39.93M | -$-66.19M | -$-162.97M | -$-138.46M | -$-64.22M |
| Free cash flow | $844.3M | $633.8M | $170.4M | $224.2M | $336.6M |
Line items
Line items
Line items
About Exelixis, Inc.
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
- CEO
- Michael Morrissey
- Employees
- 1.08K
- Beta
- 0.42
Included in
Explore
Frequently asked questions
What is the intrinsic value of Exelixis, Inc. (EXEL)?
Exelixis, Inc. (EXEL) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is EXEL undervalued?
EXEL trades at a price of $64.63 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.